SCHEMBL4481566

SCHEMBL4481566

NNC(=O)CN1CCN(n2ccc(-c3cc(Cl)c(OCc4ccccc4)cc3OCc3ccccc3)n2)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.41
▸ MAPT P10636 4/20 0.41
▸ HTT P42858 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ ERBB2 P04626 5/20 0.39
▸ EGFR P00533 3/20 0.39
▸ BACE1 P56817 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ AURKA O14965 1/20 0.37
▸ PTGER1 P34995 1/20 0.37
▸ ACHE P22303 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NOTUM Q6P988 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484388 0.78 BACE1 (0.43) ALDH1A1MAPTHTTLMNAERBB2
SCHEMBL13627470 0.71 ALDH1A1 (0.44) ALDH1A1MAPTHTTLMNABACE1
SCHEMBL14859632 0.70 HRH3 (0.64) ALDH1A1MAPTHTTLMNARAB9A
SCHEMBL14860754 0.70 KMT2A (0.58) ALDH1A1HTTLMNARAB9ASMN1; SMN2
SCHEMBL4084709 0.67 KMT2A (0.73) ALDH1A1MAPTLMNAKMT2A
SCHEMBL1577832 0.65 MRGPRX4 (0.46) RAB9ASMN1; SMN2CYP1A2CYP2C19PTGER1
SCHEMBL20381852 0.65 KMT2A (0.59) ALDH1A1MAPTLMNACYP2D6MAPK1
SCHEMBL20184188 0.64 KMT2A (0.68) ALDH1A1MAPTLMNAKMT2A
SCHEMBL3103763 0.63 L3MBTL1 (0.44) RAB9ASMN1; SMN2PTGER1NOTUM
SCHEMBL5274578 0.63 BRD4 (0.44) ALDH1A1MAPTHTTLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612201-B2 Pyrazole compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2009-11-03 — — US disclosed
US-20060148817-A1 Pyrazole compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2006-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148817-A1 Pyrazole compounds NRAS, HSP90AB1, HSP90AA1 ALDH1A1 883/4885MAPT 4095/4885HTT 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback